Key result
DOACs compared to warfarin in severely obese AF patients lack reported results in the abstract.
Why the study?
Data regarding DOAC use in AF patients with severe obesity (BMI ≥40 kg/m2) remain limited due to altered pharmacokinetics and under-representation in clinical trials.
Do DOACs improve clinical outcomes in severely obese (BMI ≥40 kg/m2) patients with atrial fibrillation compared to warfarin?
Do DOACs improve clinical outcomes in severely obese (BMI ≥40 kg/m2) patients with atrial fibrillation compared to warfarin?
Real-world propensity-matched study comparing outcomes of DOACs and warfarin in severely obese patients with AF, indicating unmet needs in clinical evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Odukudu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: